Literature DB >> 12362415

Quadriplegic areflexic ICU illness: selective thick filament loss and normal nerve histology.

Howard W Sander1, Marianna Golden, Moris J Danon.   

Abstract

Areflexic quadriplegia that occurs in the intensive care unit (ICU) is commonly ascribed to critical illness polyneuropathy based upon electrophysiology or muscle light microscopy. However, electron microscopy often documents a selective thick filament loss myopathy. Eight ICU patients who developed areflexic quadriplegia underwent biopsy. Seven patients had received steroids, and 2 had also received paralytic agents. Electrodiagnostic studies revealed absent or low-amplitude motor responses in 7. Sensory responses were normal in 5 of 6 and absent in 1. Initial electromyography revealed absent (n = 3), small (n = 3), or polyphasic (n = 1) motor unit potentials, and diffuse fibrillation potentials (n = 5). In all 8, light microscopy of muscle revealed numerous atrophic-angulated fibers and corelike lesions, and electron microscopy revealed extensive thick filament loss. Morphology of sural and intramuscular nerves, and, in one autopsied case, of the obturator nerve and multiple nerve roots, was normal. Although clinical, electrodiagnostic, and light microscopic features mimicked denervating disease, muscle electron microscopy revealed thick filament loss, and nerve histology was normal. This suggests that areflexic ICU quadriplegia is a primary myopathy and not an axonal polyneuropathy. Copyright 2002 Wiley Periodicals, Inc. Muscle Nerve 26: 499-505, 2002

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12362415     DOI: 10.1002/mus.10233

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  13 in total

Review 1.  [Intensive care unit-acquired weakness in the critically ill : critical illness polyneuropathy and critical illness myopathy].

Authors:  K Judemann; D Lunz; Y A Zausig; B M Graf; W Zink
Journal:  Anaesthesist       Date:  2011-10       Impact factor: 1.041

Review 2.  [Intensive care unit acquired weakness. Pathogenesis, treatment, rehabilitation and outcome].

Authors:  M Ponfick; K Bösl; J Lüdemann-Podubecka; G Neumann; M Pohl; D A Nowak; H-J Gdynia
Journal:  Nervenarzt       Date:  2014-02       Impact factor: 1.214

3.  Mechano-signalling pathways in an experimental intensive critical illness myopathy model.

Authors:  Rebeca Corpeno Kalamgi; Heba Salah; Stefano Gastaldello; Vicente Martinez-Redondo; Jorge L Ruas; Wen Fury; Yu Bai; Jesper Gromada; Roberta Sartori; Denis C Guttridge; Marco Sandri; Lars Larsson
Journal:  J Physiol       Date:  2016-04-24       Impact factor: 5.182

4.  Role of endotoxin in the pathogenesis of critical illness polyneuropathy.

Authors:  B Mohammadi; I Schedel; K Graf; A Teiwes; H Hecker; B Haameijer; D Scheinichen; S Piepenbrock; R Dengler; J Bufler
Journal:  J Neurol       Date:  2008-02-20       Impact factor: 4.849

5.  Risk factors in critical illness myopathy during the early course of critical illness: a prospective observational study.

Authors:  Steffen Weber-Carstens; Maria Deja; Susanne Koch; Joachim Spranger; Florian Bubser; Klaus D Wernecke; Claudia D Spies; Simone Spuler; Didier Keh
Journal:  Crit Care       Date:  2010-06-18       Impact factor: 9.097

6.  Enhanced muscle shortening and impaired Ca2+ channel function in an acute septic myopathy model.

Authors:  Oliver Friedrich; Ernst Hund; Frederic von Wegner
Journal:  J Neurol       Date:  2009-11-04       Impact factor: 4.849

7.  Electrophoretic determination of the myosin/actin ratio in the diagnosis of critical illness myopathy.

Authors:  Helena Stibler; Lars Edström; Karsten Ahlbeck; Sten Remahl; Tor Ansved
Journal:  Intensive Care Med       Date:  2003-08-12       Impact factor: 17.440

8.  Muscle paralysis and myosin loss in a patient with cancer cachexia.

Authors:  V Banduseela; J Ochala; K Lamberg; H Kalimo; L Larsson
Journal:  Acta Myol       Date:  2007-12

9.  Intensive care unit-acquired weakness (ICUAW) and muscle wasting in critically ill patients with severe sepsis and septic shock.

Authors:  Joerg C Schefold; Jeffrey Bierbrauer; Steffen Weber-Carstens
Journal:  J Cachexia Sarcopenia Muscle       Date:  2010-12-17       Impact factor: 12.910

10.  Early treatment with IgM-enriched intravenous immunoglobulin does not mitigate critical illness polyneuropathy and/or myopathy in patients with multiple organ failure and SIRS/sepsis: a prospective, randomized, placebo-controlled, double-blinded trial.

Authors:  Richard Brunner; Walter Rinner; Christine Haberler; Reinhard Kitzberger; Thomas Sycha; Harald Herkner; Joanna Warszawska; Christian Madl; Ulrike Holzinger
Journal:  Crit Care       Date:  2013-10-02       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.